S&P 500
5.048,42 -23,21 (-0,46%) Nasdaq
15.611,76 -100,99 (-0,64%) NIKKEI 225
37.780,35 +151,87 (+0,40%) Dólar/Euro
1,0726 -0,0007 (-0,06%) Petróleo Brent
89,30 +0,29 (+0,33%) Bitcoin EUR
60.095,43 +55,12 (+0,09%)
Regulus Therapeutics Inc. (RGLS)
Regulus Therapeutics Inc.
4224 Campus Point Court
Suite 210
San Diego, CA 92121
United States
858 202 6300
https://www.regulusrx.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 30
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Joseph P. Hagan M.B.A. | CEO & Director | 958,23k | N/A | 1969 |
| Ms. Crispina Calsada CPA | Chief Financial Officer | 579,3k | N/A | 1970 |
| Mr. Christopher Ray Aker J.D. | Senior VP, General Counsel & Corporate Secretary | 575,94k | N/A | 1961 |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director | N/A | N/A | 1969 |
| Mr. Daniel J. Penksa | VP of Finance & Controller | N/A | N/A | 1986 |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations | N/A | N/A | N/A |
| Dr. Rekha Garg M.D., M.S. | Senior Vice President of Clinical Development & Regulatory | N/A | N/A | N/A |
| Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine | N/A | N/A | N/A |
Descripción
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Gobierno corporativo
El ISS Governance QualityScore de Regulus Therapeutics Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
